The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.Subscribe today
Genes I wish they would find
Enough with the useless genes. Here are some that would actually come in handy.
Editor’s letter: The precision medicine issue
Precision medicine has led to incredibly effective treatments for cancer and inherited disease. But not everyone gets treated.
Finally, the drug that keeps you young
Anti-aging pioneer Judith Campisi explains how a recent breakthrough could ward off age-related disease.